Tesofensine 500mcg 100Tablets

Tesofensine (NS2330) is a synthetic phenyltropane derivative that functions as a triple monoamine reuptake inhibitor with potent activity at norepinephrine, dopamine, and serotonin transporters. Developed initially by NeuroSearch for treatment of Alzheimer's and Parkinson's diseases, tesofensine was repurposed for obesity management after clinical trials consistently revealed substantial weight loss as a prominent effect in participants.

The compound operates through a unique triple mechanism: inhibiting the reuptake of norepinephrine (NET), dopamine (DAT), and serotonin (SERT) transporters with IC50 values of 1.7 nM, 65 nM, and 11 nM respectively. This triple inhibition increases synaptic availability of these neurotransmitters, particularly within hypothalamic regions critical for appetite regulation and energy homeostasis.

Tesofensine's mechanism differs fundamentally from gut hormone-based obesity medications like GLP-1 agonists. Rather than slowing gastric emptying or mimicking incretin hormones, tesofensine directly modulates central nervous system neurochemistry to influence appetite, satiety signaling, and energy expenditure. Pharmacological studies demonstrate that tesofensine's hypophagic (appetite-suppressing) effects are primarily mediated through indirect stimulation of α1 adrenergic receptors and dopamine D1 receptors in the hypothalamus.

The compound exhibits a notably long half-life of approximately 9 days (220 hours) and is metabolized primarily by cytochrome P450 3A4 to its active metabolite M1 (NS2360), which has an even longer half-life of 16 days (374 hours). This extended pharmacokinetic profile allows for once-daily oral administration and contributes to sustained therapeutic effects on body weight regulation.

Research in diet-induced obese animal models reveals tesofensine reduces body weight more effectively in obese subjects compared to lean subjects, suggesting enhanced efficacy in the metabolic conditions for which it is intended. The compound modulates neuronal activity in the lateral hypothalamus, specifically silencing GABAergic neurons that promote feeding behavior, thereby reducing the drive to consume food while enhancing satiety responses.

Weight Loss and Fat Reduction

Tesofensine demonstrates exceptional weight loss efficacy in clinical trials, significantly outperforming previously approved anti-obesity medications. The landmark Phase IIb clinical trial published in The Lancet (TIPO-1 study) evaluated 203 obese patients randomly assigned to receive tesofensine at doses of 0.25mg, 0.5mg, or 1.0mg daily for 24 weeks alongside an energy-restricted diet. Results showed dose-dependent weight loss: the 0.25mg dose produced 4.5% additional weight loss beyond diet and placebo, the 0.5mg dose achieved 9.2% weight loss, and the 1.0mg dose resulted in 10.6% weight loss—representing approximately twice the efficacy of other approved obesity drugs available at that time.

In absolute terms, participants receiving tesofensine 0.5mg lost an average of 11.3kg over 24 weeks, while those on the 1.0mg dose lost an average of 12.8kg, compared to just 2.2kg in the placebo group. The 48-week extension trial (TIPO-4) demonstrated sustained efficacy, with participants maintaining a total mean weight loss of 13-14kg over the extended treatment period, confirming long-term effectiveness without significant tolerance development.

Animal studies in diet-induced obese rats show tesofensine (2.0mg/kg) produces marked weight reduction accompanied by strong hypophagic responses. Chronic 16-day administration resulted in an average 8.6% decrease in body weight relative to baseline, with a 13.8% relative weight loss compared to vehicle controls. Importantly, tesofensine reduces daily food intake by approximately 49% during the initial treatment period, demonstrating powerful appetite suppression that drives the observed weight loss.

Microstructural analysis of feeding behavior reveals tesofensine significantly reduces total number of meals, average meal size, and average meal duration while dramatically increasing latency to first meal. These effects indicate tesofensine enhances satiety signaling and reduces the motivation to seek food, rather than simply causing general malaise or aversion to food consumption.

Sources:

• Astrup A, et al. "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." Lancet. 2008;372(9653):1906-1913. https://pubmed.ncbi.nlm.nih.gov/18950853/
• Axel AMD, et al. "Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat." Neuropsychopharmacology. 2010;35(7):1464-1476. https://pmc.ncbi.nlm.nih.gov/articles/PMC3055463/
• Astrup A, et al. "Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease." Obesity (Silver Spring). 2008;16(6):1363-1369. https://pubmed.ncbi.nlm.nih.gov/18356831/

Body Composition and Lean Mass Preservation

Research demonstrates tesofensine produces favorable changes in body composition, with weight loss derived primarily from fat mass reduction while preserving lean muscle tissue. Clinical trial data indicates tesofensine-induced weight loss consists predominantly of fat mass loss with notable preservation of lean body mass, a critical distinction from general caloric restriction which typically results in proportional loss of both fat and muscle tissue.

Studies using dual-energy X-ray absorptiometry (DEXA) body composition analysis confirm tesofensine treatment significantly reduces total fat mass and visceral adipose tissue while maintaining skeletal muscle mass. This muscle-sparing effect during weight loss is particularly valuable for maintaining metabolic rate, physical function, and long-term weight loss sustainability, as preservation of lean mass helps prevent the metabolic adaptations that typically promote weight regain.

Animal studies in diet-induced obesity models show tesofensine treatment produces selective reduction in adiposity with improvements in insulin sensitivity, reductions in plasma lipids, and decreased accumulation of abdominal and subcutaneous fat mass. The compound's ability to reduce fat tissue while maintaining protein mass is evidenced by body composition analyses showing that weight reduction occurs through specific targeting of adipose deposits rather than generalized tissue catabolism.

The mechanisms underlying muscle preservation likely involve tesofensine's enhancement of dopaminergic and noradrenergic signaling, which may support protein synthesis pathways and reduce muscle atrophy signaling. Additionally, by increasing satiety rather than simply reducing total energy availability, tesofensine may help maintain adequate protein intake even during caloric restriction, supporting lean mass preservation.

Sources:

• Astrup A, et al. "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." Lancet. 2008;372(9653):1906-1913. https://pubmed.ncbi.nlm.nih.gov/18950853/
• Hansen HH, et al. "The obesity drug tesofensine increases ATP content, phosphorylation of AMPK and CREB, and expression of CPT1 in rat muscle." Peptides. 2010;31(6):1162-1170. https://pubmed.ncbi.nlm.nih.gov/20347900/

Metabolic Health and Insulin Sensitivity

Tesofensine demonstrates significant beneficial effects on metabolic parameters beyond weight loss alone. Clinical trial data reveals improvements in insulin sensitivity and glucose metabolism in obese patients treated with tesofensine, with reductions in blood sugar levels observed across all dosage groups. These metabolic improvements appear partially independent of weight loss magnitude, suggesting direct metabolic effects in addition to benefits derived from reduced adiposity.

Animal studies in diet-induced obese rats show tesofensine treatment produces improvements in metabolic status including increased insulin sensitivity, reductions in plasma lipid levels, and enhanced glucose homeostasis. The compound's effects on insulin sensitivity make it particularly relevant for obese individuals at risk for type 2 diabetes or those with existing metabolic syndrome.

Research demonstrates tesofensine increases 24-hour fat oxidation by approximately 15% while reducing protein oxidation, indicating a favorable shift in substrate utilization toward lipid metabolism. This metabolic flexibility enhancement—the capacity to efficiently switch between carbohydrate and fat oxidation—is a key marker of metabolic health and insulin sensitivity. Improved fat oxidation helps mobilize stored adipose tissue for energy, contributing to sustained fat loss while preserving lean tissue.

Clinical observations show tesofensine treatment improves lipid profiles, with reductions in total cholesterol and low-density lipoprotein (LDL) cholesterol levels. These improvements in cardiovascular risk markers, combined with enhanced insulin sensitivity and glucose metabolism, suggest tesofensine may provide comprehensive metabolic benefits for obese individuals with comorbid metabolic conditions.

The compound's effects on insulin sensitivity and triglyceride levels were specifically noted in clinical commentary, with researchers emphasizing that the aim of weight-loss therapy extends beyond weight reduction to include reduction in risk of type 2 diabetes, metabolic syndrome, and cardiovascular disease—goals that tesofensine appears to address through its documented improvements in insulin sensitivity and triglyceride levels.

Sources:

• Astrup A, et al. "Tesofensine and weight loss – Authors' reply." Lancet. 2009;373(9665):719-720. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60434-7/fulltext
• Hansen HH, et al. "The obesity drug tesofensine increases ATP content, phosphorylation of AMPK and CREB, and expression of CPT1 in rat muscle." Peptides. 2010;31(6):1162-1170. https://pubmed.ncbi.nlm.nih.gov/20347900/

Energy Expenditure and Metabolic Rate

Beyond appetite suppression, tesofensine demonstrates effects on energy expenditure and metabolic rate that contribute to its anti-obesity properties. While the compound's primary mechanism involves reducing food intake through enhanced satiety, evidence suggests it also modestly increases resting energy expenditure through stimulation of noradrenergic pathways. Research indicates that stimulation of monoaminergic neurotransmission can impact metabolic rate by increasing energy expenditure either directly through activation of peripheral β3 adrenergic receptors in brown adipose tissue (increasing thermogenesis) or indirectly through central dopamine receptor-dependent increases in motor activity.

Animal studies demonstrate that chronic tesofensine treatment produces sustained weight loss even as tolerance to the hypophagic effect gradually develops, indicating additional factors beyond appetite regulation contribute to maintaining maximal weight loss. This notion is supported by observations that monoamine reuptake inhibitors, including dual norepinephrine/serotonin and norepinephrine/dopamine reuptake inhibitors, produce combined effects on both feeding behavior and metabolic rate through complementary mechanisms.

Clinical observations suggest tesofensine may increase resting energy expenditure by approximately 6% after 14 days of treatment, directly attributable to the compound rather than external factors. This metabolic enhancement, while modest compared to the robust appetite suppression effects, provides an additional mechanism contributing to the compound's exceptional weight loss efficacy. The norepinephrine component of tesofensine's triple mechanism likely mediates these metabolic rate increases through sympathetic nervous system activation.

Research in diet-induced obese rats shows tesofensine increases energy expenditure through multiple pathways involving α1 adrenergic receptor and dopamine D1 receptor stimulation. These receptor systems influence both thermogenesis and physical activity levels, contributing to increased total energy expenditure. The compound's ability to enhance both sides of the energy balance equation—reducing energy intake while modestly increasing energy expenditure—explains its superior efficacy compared to agents targeting only appetite or metabolism alone.

Sources:

• Axel AMD, et al. "Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat." Neuropsychopharmacology. 2010;35(7):1464-1476. https://pmc.ncbi.nlm.nih.gov/articles/PMC3055463/
• Billes SK, Cowley MA. "Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis." Neuropsychopharmacology. 2008;33(6):1287-1297. https://pubmed.ncbi.nlm.nih.gov/17687262/

Neurological Mechanisms and Hypothalamic Function

Tesofensine exerts its anti-obesity effects through specific modulation of hypothalamic neuronal circuits that regulate feeding behavior and energy homeostasis. Recent research demonstrates tesofensine silences GABAergic neurons in the lateral hypothalamus (LH), a brain region critically involved in promoting feeding behavior. Using advanced electrophysiological techniques, optogenetic activation, and chemogenetic silencing approaches, studies reveal tesofensine inhibits a specific subset of LH GABAergic neurons, reducing their ability to stimulate food-seeking behavior and consumption.

The compound's effects are mediated primarily through indirect stimulation of α1 adrenergic receptors and dopamine D1 receptors within hypothalamic regions. Pharmacological antagonist studies demonstrate that co-administration of prazosin (α1 antagonist) almost completely reverses tesofensine-induced appetite suppression, while SCH23390 (D1 antagonist) produces partial reversal. In contrast, antagonists of α2 adrenergic, dopamine D2, dopamine D3, and serotonin 5-HT2A/C receptors fail to affect tesofensine's hypophagic properties, indicating the specific receptor pathways responsible for its therapeutic effects.

Research shows tesofensine differentially modulates neuronal ensembles and population activity in the lateral hypothalamus, with greater weight loss effects observed in obese rats compared to lean rats. This enhanced efficacy in obesity suggests the compound may normalize dysfunctional hypothalamic signaling present in obese states. Diet-induced obese animals exhibit indices of altered central monoaminergic neurotransmission, including reduced hypothalamic α1 adrenoceptor binding, enhanced electrophysiological responsiveness to norepinephrine application, decreased basal hypothalamic serotonin and dopamine levels, and reduced mesolimbic dopamine activity.

The compound increases hypothalamic norepinephrine and dopamine availability through transporter blockade, enhancing activation of specific receptor subtypes that promote satiety and reduce feeding motivation. Unlike stimulant appetite suppressants like phentermine that induce stereotypic behaviors and head-weaving, tesofensine causes minimal stereotypy at therapeutic doses, indicating a more refined pharmacological profile with reduced central stimulation side effects while maintaining robust anti-obesity efficacy.

Sources:

• Reynolds JC, et al. "Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons." PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11042726/
• Axel AMD, et al. "Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat." Neuropsychopharmacology. 2010;35(7):1464-1476. https://pmc.ncbi.nlm.nih.gov/articles/PMC3055463/